Director Bruce Polsky of Atea Pharmaceuticals, Inc. filed a Form 4 on November 19, 2026, disclosing the sale of 8,750 shares of common stock at a weighted average price of $4.0341 per share.
Key Highlights
- Reporting person: Bruce Polsky, Director at Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
- Transaction: Disposition (Code S) of 8,750 shares of common stock on November 19, 2026
- Weighted average price: $4.0341 per share, with individual transactions ranging from $4.00 to $4.04 per share
- Post-transaction holdings: 149,830 shares of common stock held directly following the reported sale
- Stated purpose: The filing notes all sale transactions "were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes"
Bruce Polsky's November 2026 Share Sale at Atea Pharmaceuticals
According to the Form 4 filed with the U.S. Securities and Exchange Commission, Bruce Polsky, identified as a Director of Atea Pharmaceuticals, Inc., disposed of 8,750 shares of common stock on November 19, 2026. The shares were sold in multiple transactions at per-share prices ranging from $4.00 to $4.04, producing a reported weighted average price of $4.0341. The filing states that Polsky undertakes to provide, upon request to the SEC staff, the issuer, or any stockholder, full information regarding the number of shares sold at each separate price within that range.
The filing's remarks section states that "all sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes." Following the reported transaction, Polsky directly holds 149,830 shares of common stock, according to the filing. No derivative securities transactions were reported in Table II of the form.
The Form 4 was signed by Andrea Corcoran as Attorney-in-Fact for Bruce Polsky and was dated November 19, 2026, the same date as the earliest transaction reported. The filing does not indicate that any box was checked to signify a Rule 10b5-1(c) plan in connection with this transaction.
What Was Disclosed
Atea Pharmaceuticals Director Bruce Polsky reported the sale of 8,750 common shares at a weighted average of $4.0341 on November 19, 2026, citing option exercise cost and tax planning purposes, leaving him with 149,830 directly held shares.




Please wait processing your request...